Enovis Corporation (ENOV) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Engine safety override at $25.76: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Below long-term trend.
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment... Read more
Sell if holding. Engine safety override at $25.76: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 63. Score 5.9/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — Enovis Corporation
Latest news
- Despite fast-paced momentum, Enovis (ENOV) is still a bargain stock - MSN — MSN positive
- Despite Fast-paced Momentum, Enovis (ENOV) Is Still a Bargain Stock - Yahoo Finance — Yahoo Finance positive
- Is Enovis Corp (ENOV) a Bargain After 4.7% Drop? GF Value Says U - GuruFocus — GuruFocus neutral
- Enovis Corporation (ENOV) Stock: Is It Overpriced | Q4 2025: Profit Exceeds Views - Trending Entry Points - Newser — Newser positive
- William Blair Assigns Outperform Rating to Enovis (ENOV) - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $25.76: Risk below floor (3.0 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 63. Prior stop was $23.96. Score 5.9/10, moderate confidence.
Take-profit target: $37.41 (+45.2% upside). Prior stop was $23.96. Stop-loss: $23.96.
Risk below floor (3.0 < 3.0).
Enovis Corporation trades at a P/E of N/A (forward 6.2). TrendMatrix value score: 9.2/10. Verdict: Sell.
18 analysts cover ENOV with a consensus score of 4.2/5. Average price target: $43.
What does Enovis Corporation do?Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the...
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.